SCHEMBL33493

SCHEMBL33493

Cc1cc(CBr)ccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.50
RARB P10826 1/20 0.49
RXRA P19793 2/20 0.46
HMGB1 P09429 1/20 0.46
CXCL12 P48061 1/20 0.46
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
RXRB P28702 2/20 0.44
CFD P00746 1/20 0.41
AGTR1 P30556 1/20 0.40
AGTR2 P50052 1/20 0.40
SRD5A2 P31213 1/20 0.40
KLKB1 P03952 1/20 0.40
CTSB P07858 1/20 0.40
MMP9 P14780 1/20 0.40
DNMT1 P26358 1/20 0.40
DNMT3B Q9UBC3 1/20 0.40
DNMT3L Q9UJW3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31568856 0.85 RARB (0.50) NR1H4RARBRXRAHMGB1CXCL12
SCHEMBL1020426 0.85 RARB (0.50) NR1H4RARBRXRAHMGB1CXCL12
SCHEMBL1179532 0.85 CYP4F2 (0.49) NR1H4RARBHMGB1CXCL12CYP4F2
SCHEMBL9403206 0.84 ALDH1A1 (0.47) NR1H4RARBCES2CES1CFD
SCHEMBL107902 0.84 HMGB1 (0.58) NR1H4RARBRXRAHMGB1CXCL12
SCHEMBL31635558 0.83 CYP4F2 (0.47) NR1H4RARBRXRAHMGB1CXCL12
SCHEMBL6223649 0.83 CYP4F2 (0.44) NR1H4CYP4F2CYP4A11CES2CES1
SCHEMBL1627397 0.82 NR1H4 (0.51) NR1H4RARBRXRAHMGB1CXCL12
SCHEMBL2343149 0.82 ALDH1A1 (0.55) NR1H4RARBRXRAHMGB1CXCL12
SCHEMBL2857663 0.82 KLKB1 (0.48) CYP4F2CYP4A11CES2CES1CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114414684-B Florarana intermediate and detection method of isomer thereof 丽珠集团新北江制药股份有限公司 2023-05-23 CN claimed
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2025-05-29 US disclosed
US-20250109095-A1 METHOD FOR PREPARING OXIME DERIVATIVE SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-04-03 US disclosed
US-12054471-B2 Thiocycloheptyne derivatives and their use CRISTAL DELIVERY B.V. (NL) 2024-08-06 US disclosed
WO-2024105159-A1 LIGANDS OF THE M6A-RNA READERS UNIVERSITY OF ZURICH (CH) 2024-05-23 WO disclosed
WO-2024020684-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2024-02-01 WO disclosed
CN-112707809-B Method for preparing oxazoline insecticide fluorine Lei Lana intermediate 丽珠集团新北江制药股份有限公司 2023-08-29 CN disclosed
CN-114763356-B Pyrrolo-benzodiazepine compound, and preparation method and application thereof 沈阳药科大学 2023-06-20 CN disclosed
WO-2023104165-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST 上海维申医药有限公司 2023-06-15 WO disclosed
WO-2023101319-A1 METHOD FOR PREPARING OXIME DERIVATIVE 서울대학교산학협력단 2023-06-08 WO disclosed
US-5171748-A For hypertension, cardiovascular disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-12-15 US disclosed
US-5053164-A For high speed switching MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1991-10-01 US disclosed
EP-0110405-B1 ANTIINFLAMMATORY/ANTIALLERGIC COMPOUNDS RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) 1990-12-27 EP disclosed
EP-0399732-A1 Benzimidazole derivatives ZENECA LIMITED (GB) 1990-11-28 EP disclosed
US-4943651-A Novel substitued naphthalene compounds and liquid crystal compositions containing same MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1990-07-24 US disclosed
EP-0332409-A2 Novel substituted naphthalene compounds and liquid crystal compositions containing same MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1989-09-13 EP disclosed
US-4866076-A THROMBOXANE ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-09-12 US disclosed
US-4778931-A ENZYME INHIBITORS USV PHARMACEUTICAL CORPORATION (US) 1988-10-18 US disclosed
US-4567184-A Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies USV PHARMACEUTICAL CORPORATION (US) 1986-01-28 US disclosed
EP-0110405-A2 Antiinflammatory/antiallergic compounds RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) 1984-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109095-A1 METHOD FOR PREPARING OXIME DERIVATIVE NOS2, NOS1, NOS3 NR1H4 4836/4885RARB 2660/4885RXRA 3623/4885
US-12054471-B2 Thiocycloheptyne derivatives and their use CYP7A1, CYP3A5, ABCB1 NR1H4 86/4885RARB 3563/4885RXRA 4104/4885
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF PAICS, ENTPD5, PNP NR1H4 686/4885RARB 842/4885RXRA 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.